Celltrion Reports Positive Data For High-Concentration Adalimumab
Phase III Trials Cover Two Delivery Methods For CT-P17
Celltrion’s phase III study comparing the pharmacokinetics, efficacy and safety profile of its CT-P17 high-concentration adalimumab biosimilar to Humira has yielded positive results. The company is presenting the results at the American College of Rheumatology Convergence 2020.
You may also be interested in...
Alvotech has announced the filing of its AVT02 higher-strength adalimumab version of Humira 100mg/ml with both the FDA and the EMA, as well as disclosing expected decision dates. Teva will market the biosimilar in the US and Stada in Europe.
Alvotech’s AVT02 proposed adalimumab biosimilar has seen positive results from two clinical trials. The high concentration dosage form of AVT02 differentes it from most of its biosimilar competitors.
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.